VivoSeq
Other

Surgical Site Infection

5

Pipeline Programs

10

Active Trials

1

Companies Involved

Surgical Site Infection is an early-stage landscape with 5 programs across 1 company. The most active players are Merck & Co.. 1 program is in Phase 3.

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

76/100

Attrition Rate

12/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Trial Status

41

clinical trials

Completed16 · 39%
Unknown status10 · 24%
Recruiting9 · 22%
Terminated3 · 7%
Withdrawn2 · 5%
Active, not recruiting1 · 2%

Trial Activity

41 trials

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)